Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075)

This multicentre, open-label study investigated the safety and efficacy of Gammaplex, a 5% Intravenous Immunoglobulin (IVIg), in patients with idiopathic (immune) thrombocytopenic purpura (ITP). Patients were between the ages of 6 and 70 years; had ITP for at least six months and had a platelet coun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-06, Vol.9 (6), p.e96600
Hauptverfasser:	Dash, Clive H, Gillanders, Kate R, Stratford Bobbitt, Margaret E, Gascoigne, Ernie W, Leach, Samantha J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anemia Biology and Life Sciences Bleeding Blood platelets Child Clinical trials Confidence intervals Dehydration Demography Dose-Response Relationship, Drug Drug dosages Effectiveness Ethics FDA approval Female Fever Headache Hematology Hemorrhage - chemically induced Humans Idiopathic thrombocytopenic purpura Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous - administration & dosage Immunoglobulins, Intravenous - adverse effects Immunoglobulins, Intravenous - pharmacokinetics Immunoglobulins, Intravenous - therapeutic use Infusion Intravenous administration Laboratories Male Medical research Medical technology Medicine and health sciences Middle Aged Patients Platelet Count Platelets Public health Purpura Purpura, Thrombocytopenic, Idiopathic - blood Purpura, Thrombocytopenic, Idiopathic - drug therapy Research and Analysis Methods Safety Side effects Statistical analysis Thrombocytopenic purpura Thromboembolism Treatment Outcome Vomiting Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!